These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 20645988)

  • 21. Delayed postconditioning in the mouse heart in vivo.
    Roubille F; Franck-Miclo A; Covinhes A; Lafont C; Cransac F; Combes S; Vincent A; Fontanaud P; Sportouch-Dukhan C; Redt-Clouet C; Nargeot J; Piot C; Barrère-Lemaire S
    Circulation; 2011 Sep; 124(12):1330-6. PubMed ID: 21875909
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Signalling pathways in ischaemic postconditioning.
    Hausenloy DJ
    Thromb Haemost; 2009 Apr; 101(4):626-34. PubMed ID: 19350104
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical perspectives on reperfusion injury in acute myocardial infarction.
    Bainey KR; Armstrong PW
    Am Heart J; 2014 May; 167(5):637-45. PubMed ID: 24766972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contribution of apoptosis in myocardial reperfusion injury and loss of cardioprotection in diabetes mellitus.
    Badalzadeh R; Mokhtari B; Yavari R
    J Physiol Sci; 2015 May; 65(3):201-15. PubMed ID: 25726180
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prevention and treatment of microvascular obstruction-related myocardial injury and coronary no-reflow following percutaneous coronary intervention: a systematic approach.
    Jaffe R; Dick A; Strauss BH
    JACC Cardiovasc Interv; 2010 Jul; 3(7):695-704. PubMed ID: 20650430
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interaction of Cardiovascular Nonmodifiable Risk Factors, Comorbidities and Comedications With Ischemia/Reperfusion Injury and Cardioprotection by Pharmacological Treatments and Ischemic Conditioning.
    Ferdinandy P; Andreadou I; Baxter GF; Bøtker HE; Davidson SM; Dobrev D; Gersh BJ; Heusch G; Lecour S; Ruiz-Meana M; Zuurbier CJ; Hausenloy DJ; Schulz R
    Pharmacol Rev; 2023 Jan; 75(1):159-216. PubMed ID: 36753049
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protecting the myocardial cell during coronary revascularization. The William W. L. Glenn Lecture.
    Levitsky S
    Circulation; 2006 Jul; 114(1 Suppl):I339-43. PubMed ID: 16820597
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Remote ischemic preconditioning for myocardial protection: update on mechanisms and clinical relevance.
    Gill R; Kuriakose R; Gertz ZM; Salloum FN; Xi L; Kukreja RC
    Mol Cell Biochem; 2015 Apr; 402(1-2):41-9. PubMed ID: 25552250
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Realizing the clinical potential of ischemic preconditioning and postconditioning.
    Yellon DM; Hausenloy DJ
    Nat Clin Pract Cardiovasc Med; 2005 Nov; 2(11):568-75. PubMed ID: 16258568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Myocardial protection with postconditioning is not enhanced by ischemic preconditioning.
    Halkos ME; Kerendi F; Corvera JS; Wang NP; Kin H; Payne CS; Sun HY; Guyton RA; Vinten-Johansen J; Zhao ZQ
    Ann Thorac Surg; 2004 Sep; 78(3):961-9; discussion 969. PubMed ID: 15337028
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The impairment of preconditioning-mediated cardioprotection in pathological conditions.
    Balakumar P; Singh H; Singh M; Anand-Srivastava MB
    Pharmacol Res; 2009 Jul; 60(1):18-23. PubMed ID: 19427581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of hypercholesterolaemia on myocardial function, ischaemia-reperfusion injury and cardioprotection by preconditioning, postconditioning and remote conditioning.
    Andreadou I; Iliodromitis EK; Lazou A; Görbe A; Giricz Z; Schulz R; Ferdinandy P
    Br J Pharmacol; 2017 Jun; 174(12):1555-1569. PubMed ID: 28060997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myocardial postconditioning is lost in vascular nitrate tolerance.
    Fekete V; Murlasits Z; Aypar E; Bencsik P; Sárközy M; Szénási G; Ferdinandy P; Csont T
    J Cardiovasc Pharmacol; 2013 Sep; 62(3):298-303. PubMed ID: 23669719
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Endogenous Cardioprotective Agents: Role in Pre and Postconditioning.
    Penna C; Granata R; Tocchetti CG; Gallo MP; Alloatti G; Pagliaro P
    Curr Drug Targets; 2015; 16(8):843-67. PubMed ID: 25751010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Effects of ischemia postconditioning on ischemia-reperfusion injury and reperfusion injury salvage kinase signal transduction pathways in isolated mouse hearts].
    Zhang JF; Ma YT; Yang YN; Gao XM; Liu F; Chen BD; Li XM; Xiang Y
    Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Feb; 36(2):161-6. PubMed ID: 19099957
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mitochondria in postconditioning.
    Boengler K; Heusch G; Schulz R
    Antioxid Redox Signal; 2011 Mar; 14(5):863-80. PubMed ID: 20578961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The basis of ischemia-reperfusion and myocardial protection].
    Benhabbouche S; Crola da Silva C; Abrial M; Ferrera R
    Ann Fr Anesth Reanim; 2011 May; 30 Suppl 1():S2-16. PubMed ID: 21703480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Past and present course of cardioprotection against ischemia-reperfusion injury.
    Liem DA; Honda HM; Zhang J; Woo D; Ping P
    J Appl Physiol (1985); 2007 Dec; 103(6):2129-36. PubMed ID: 17673563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reperfusion injury in humans: a review of clinical trials on reperfusion injury inhibitory strategies.
    Dirksen MT; Laarman GJ; Simoons ML; Duncker DJ
    Cardiovasc Res; 2007 Jun; 74(3):343-55. PubMed ID: 17306241
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Myocardial postconditioning: next step to cardioprotection.
    Rohilla A; Rohilla S; Kushnoor A
    Arch Pharm Res; 2011 Sep; 34(9):1409-15. PubMed ID: 21975801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.